CoChat
Sign Up
Cited by 246HER2/EGFR in Cancer ResearchBreast Cancer Treatment StudiesGastric Cancer Management and Outcomes

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer

Hurley, Judith, Doliny, Philomena, Reis, Isildinha, Silva, Orlando, Gomez-Fernandez, Carmen, Velez, Pedro, Pauletti, Giovanni, Powell, Jodeen E., Pegram, Mark D., Slamon, Dennis J.·2006·Journal of Clinical Oncology
DOI 10.1200/jco.2005.02.8886
Open this paper in CoChat — free account

Abstract

PURPOSE: To evaluate the efficacy and safety of docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2 (HER2) -positive, locally advanced breast cancer (LABC). PATIENTS AND METHODS: Forty-eight patients with immunohistochemistry-confirmed HER2-positive LABC or inflammatory breast cancer received 12 weeks of docetaxel, cisplatin, and trastuzumab with filgrastim, followed by surgery, adjuvant doxorubicin and cyclophosphamide, and locoregional radiotherapy with or without tamoxifen. The primary end point was pathologic complete response (pCR) in breast. RESULTS: Baseline mean tumor size was 9.2 cm (range, 4 to 32 cm). pCR occurred in breast in 11 patients (23%; 95% CI, 12% to 37%) and breast and axilla in eight patients (17%; 95% CI, 8% to 30%). pCR rates in breast (HER2 positive, seven of 30 patients, 23% v HER2 negative, four of 18 patients, 22%; P > .05) and breast and axilla (four of 30 patients, 13% v four of 18 patients, 22%, respectively; P > .05) were similar regardless of HER2 status by fluorescence in situ hybridization (FISH). At a median follow-up time of 43 months, 4-year progression-free survival (PFS) rate was 81% (95% CI, 64% to 90%); overall survival (OS) rate was 86% (95% CI, 71% to 94%). In patients with pCR in breast and axilla, PFS and OS rates were 100% (95% CI, inestimable). In patients without pCR, PFS rate was 76% (95% CI, 57% to 88%; P = .15, log-rank test), and OS rate was 83% (95% CI, 66% to 92%; P = .21). Survival rates were similar regardless of FISH status. There were only two grade 4 adverse events. CONCLUSION: Twelve weeks of docetaxel, cisplatin, and trastuzumab is clinically active and leads to excellent survival in patients with large, HER2-positive tumors.

Overview

Integrity signals

Registry

Crossref · 10.1200/jco.2005.02.8886

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 38 references

Research works printed but not linked: 2

  1. 10.1200/JCO.20.3.719 · DOI · Paper page
  2. Mass RD, Press M, Anderson S, et al: Improved survival benefit from herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH). Proc Am Soc Clin Oncol 20:22a,2001, (abstr 85)

Cited by

Sorted by citations

Items 101–200 of 246

Related

See all

Metadata

Authors
Hurley, J., Doliny, P., Reis, I., Silva, O., Gomez-Fernandez, C., Velez, P., Pauletti, G., Powell, J. E., Pegram, M. D., & Slamon, D. J.
Affiliations
University of Miami (US)
ORCID
Venue
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Published
2006-04-20
Volume
24
Issue
12
Pages
1831-1838
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
DOI
10.1200/jco.2005.02.8886
OpenAlex
W2161791469
Cited by
245
References
38
Citations by year
2025: 1 · 2024: 1 · 2023: 3 · 2022: 8 · 2021: 15 · 2020: 4 · 2019: 10 · 2018: 5 · 2017: 5 · 2016: 12 · 2015: 10 · 2014: 13 · 2013: 17 · 2012: 18
FWCI
11.48
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
Keywords
docetaxel, cisplatin, trastuzumab, HER2-positive breast cancer, locally advanced breast cancer, inflammatory breast cancer, neoadjuvant chemotherapy, pathological complete response, progression-free survival, overall survival, treatment toxicity, locoregional radiotherapy
MeSH terms
Trastuzumab, Docetaxel, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Cisplatin, Female, Humans, Infusions, Intravenous, Middle Aged, Survival Analysis, Treatment Outcome, Disease Progression, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Taxoids, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review